chromosome 17 open reading frame 75Genealiases: NJMU-R1 · SRI2
Q-omics provides the consensus-scored C17orf75 profile across patient tissues and cancer cell-line models. C17orf75 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, C17orf75 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, C17orf75 RNA expression shows 23,719 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, KICH, and LSCC as cancer lineages where C17orf75 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf75 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf75 survival associations across molecular data types. C17orf75 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf75 RNA expression–survival associations across cancer types. High C17orf75 expression shows unfavorable associations in LIHC and BLCA, but favorable associations in UCS, READ, SKCM and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for C17orf75 RNA expression.
This table summarizes C17orf75 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for C17orf75. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf75 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, COAD, LIHC and LUAD. The KICH box plot shows higher C17orf75 RNA expression in normal versus tumor tissue (log2 FC = −1.359, t-test p < 0.001).
This table shows molecular features associated with C17orf75 in patient tissues and cancer cell lines. In patient samples, C17orf75 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf75 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
